Growth Hormone Deficiency - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Growth Hormone Deficiency - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Growth Hormone Deficiency - Pipeline Review, H1 2015', provides an overview of the Growth Hormone Deficiency's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Growth Hormone Deficiency pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Growth Hormone Deficiency
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Growth Hormone Deficiency pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Growth Hormone Deficiency Overview 9
Therapeutics Development 10
Pipeline Products for Growth Hormone Deficiency - Overview 10
Pipeline Products for Growth Hormone Deficiency - Comparative Analysis 11
Growth Hormone Deficiency - Therapeutics under Development by Companies 12
Growth Hormone Deficiency - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Growth Hormone Deficiency - Products under Development by Companies 19
Growth Hormone Deficiency - Companies Involved in Therapeutics Development 21
Aeterna Zentaris Inc. 21
Aileron Therapeutics, Inc. 22
Ascendis Pharma A/S 23
Biogenomics Limited 24
Bolder Biotechnology, Inc. 25
Braasch Biotech LLC 26
CJ CheilJedang Corp. 27
Critical Pharmaceuticals Limited 28
Delpor, Inc. 29
Emisphere Technologies, Inc. 30
Flamel Technologies S.A. 31
Genexine, Inc. 32
HanAll Biopharma Co., Ltd. 33
Hanmi Pharmaceuticals, Co. Ltd. 34
Inbiopro Solutions Pvt. Ltd. 35
LG Life Sciences, Ltd. 36
OPKO Health, Inc. 37
Pfenex Inc. 38
Prometheon Pharma, LLC 39
Teva Pharmaceutical Industries Limited 40
Versartis, Inc. 41
XL-protein GmbH 42
Growth Hormone Deficiency - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ACP-001 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
albutropin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ALRN-5281 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BBT-031 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CJ-40002 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CP-016 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GXH-9 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HL-032 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
HM-10560A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IBPB-003HH - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
macimorelin acetate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MOD-4023 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Pegylated Somatropin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
somatropin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
somatropin - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
somatropin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
somatropin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
somatropin biobetter - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
somatropin biobetter - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
somatropin biosimilar - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
somatropin biosimilar - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
somatropin pegol - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
somatropin SR - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
somatropin true patch - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
SYN-20100504RU - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Vaccine for Growth Hormone Deficiencies - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
XL-020 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Growth Hormone Deficiency - Recent Pipeline Updates 87
Growth Hormone Deficiency - - Dormant Projects 100
Growth Hormone Deficiency - Discontinued Products 101
Growth Hormone Deficiency - Product Development Milestones 102
Featured News & Press Releases 102
Dec 29, 2014: Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study 102
Dec 15, 2014: Ascendis Pharma Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 102
Oct 30, 2014: Versartis Schedules Conference Call to Discuss Plans for Phase 3 Trial for VRS-317 in Pediatric Growth Hormone Deficiency Patients 103
Sep 18, 2014: Prometheon's CEO/CSO Invited to Deliver Oral Presentation at the European Society for Paediatric Endocrinology Meeting 104
Sep 16, 2014: Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 104
Sep 11, 2014: Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference 105
Jun 30, 2014: Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317 105
Jun 27, 2014: OPKO Granted Patent from European Patent Office for Lagova 106
Jun 25, 2014: Strong Data from Lagova Phase II Clinical Study Presented during Webcast 106
Jun 23, 2014: OPKO Announces Positive Interim Six-Month Lagova (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110

List of Tables
Number of Products under Development for Growth Hormone Deficiency, H1 2015 10
Number of Products under Development for Growth Hormone Deficiency - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Growth Hormone Deficiency - Pipeline by Aeterna Zentaris Inc., H1 2015 21
Growth Hormone Deficiency - Pipeline by Aileron Therapeutics, Inc., H1 2015 22
Growth Hormone Deficiency - Pipeline by Ascendis Pharma A/S, H1 2015 23
Growth Hormone Deficiency - Pipeline by Biogenomics Limited, H1 2015 24
Growth Hormone Deficiency - Pipeline by Bolder Biotechnology, Inc., H1 2015 25
Growth Hormone Deficiency - Pipeline by Braasch Biotech LLC, H1 2015 26
Growth Hormone Deficiency - Pipeline by CJ CheilJedang Corp., H1 2015 27
Growth Hormone Deficiency - Pipeline by Critical Pharmaceuticals Limited, H1 2015 28
Growth Hormone Deficiency - Pipeline by Delpor, Inc., H1 2015 29
Growth Hormone Deficiency - Pipeline by Emisphere Technologies, Inc., H1 2015 30
Growth Hormone Deficiency - Pipeline by Flamel Technologies S.A., H1 2015 31
Growth Hormone Deficiency - Pipeline by Genexine, Inc., H1 2015 32
Growth Hormone Deficiency - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 33
Growth Hormone Deficiency - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 34
Growth Hormone Deficiency - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 35
Growth Hormone Deficiency - Pipeline by LG Life Sciences, Ltd., H1 2015 36
Growth Hormone Deficiency - Pipeline by OPKO Health, Inc., H1 2015 37
Growth Hormone Deficiency - Pipeline by Pfenex Inc., H1 2015 38
Growth Hormone Deficiency - Pipeline by Prometheon Pharma, LLC, H1 2015 39
Growth Hormone Deficiency - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 40
Growth Hormone Deficiency - Pipeline by Versartis, Inc., H1 2015 41
Growth Hormone Deficiency - Pipeline by XL-protein GmbH, H1 2015 42
Assessment by Monotherapy Products, H1 2015 43
Number of Products by Stage and Target, H1 2015 45
Number of Products by Stage and Mechanism of Action, H1 2015 47
Number of Products by Stage and Route of Administration, H1 2015 49
Number of Products by Stage and Molecule Type, H1 2015 51
Growth Hormone Deficiency Therapeutics - Recent Pipeline Updates, H1 2015 87
Growth Hormone Deficiency - Dormant Projects, H1 2015 100
Growth Hormone Deficiency - Discontinued Products, H1 2015 101